Tumor-Infiltrating Lymphocyte-Based Risk Score for Predicting Prognosis in Gastric Cancer.
GEO
TIL
gastric cancer
immune risk score model
prognosis
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
20
12
2019
accepted:
10
09
2020
entrez:
29
10
2020
pubmed:
30
10
2020
medline:
30
10
2020
Statut:
epublish
Résumé
Tumor-infiltrating lymphocytes (TILs) in gastric cancer are closely related to clinical prognosis; however, little is known regarding the immune microenvironment in this disease. Thus, RNA-sequencing data from gastric cancer patients were downloaded from the Gene Expression Omnibus (GEO). The proportion of immune cells was determined based on a deconvolution algorithm (CIBERSORT), and gene expression profiles were analyzed in the context of clinical outcomes to construct an immune risk score. Data were analyzed using least absolute shrinkage and selection operator (LASSO) and multivariable Cox regression, to identify prognostic markers of gastric cancer survival. The model included four immune cell types: neutrophils, plasma cells, activated CD4
Identifiants
pubmed: 33117674
doi: 10.3389/fonc.2020.522015
pmc: PMC7561394
doi:
Types de publication
Journal Article
Langues
eng
Pagination
522015Informations de copyright
Copyright © 2020 Xie, Mo, Li, Cai, Ruan, Ye and Mao.
Références
Nature. 2018 Feb 22;554(7693):544-548
pubmed: 29443960
Cancer Med. 2018 Sep;7(9):4496-4508
pubmed: 30117315
Mediators Inflamm. 2015;2015:747680
pubmed: 25977601
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Oncol Rep. 2017 Nov;38(5):2959-2966
pubmed: 28901479
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Sci Signal. 2019 Sep 17;12(599):
pubmed: 31530731
J Exp Clin Cancer Res. 2019 Jan 7;38(1):6
pubmed: 30616627
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
PLoS Med. 2016 Dec 13;13(12):e1002194
pubmed: 27959923
Lancet Oncol. 2014 Oct;15(11):1224-35
pubmed: 25240821
Eur J Immunol. 2017 May;47(5):765-779
pubmed: 28393361
Oncol Res Treat. 2018;41(5):272-280
pubmed: 29705787
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
J Gastrointest Oncol. 2016 Dec;7(6):848-859
pubmed: 28078109
Oncology. 2017;92 Suppl 1:50-62
pubmed: 28147363
J Immunol. 2008 Nov 15;181(10):7121-30
pubmed: 18981133
Blood. 2011 Nov 17;118(20):5487-97
pubmed: 21972292
Nat Rev Immunol. 2016 Feb;16(2):79-89
pubmed: 26688350
Clin Transl Oncol. 2014 Mar;16(3):257-65
pubmed: 23793812
Gut. 2017 May;66(5):794-801
pubmed: 26801886
Diagn Pathol. 2018 Feb 9;13(1):12
pubmed: 29426340
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
Front Immunol. 2019 May 17;10:1115
pubmed: 31156652
Lancet Oncol. 2018 May;19(5):616-628
pubmed: 29650363
Sci Rep. 2018 Apr 18;8(1):6220
pubmed: 29670256
J Exp Med. 2008 Mar 17;205(3):565-74
pubmed: 18283119
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593